FITC Mouse Anti-Human CD44
Clone L178 (RUO (GMP))
- Concentration 12.5 μg/mL
- Vol. Per Test 20 μL
- Isotype Mouse BALB/c IgG1, κ
- Reactivity Human (QC Testing)
- Application
Flow cytometry (Routinely Tested)
- Immunogen Human TCR γδ+ Thymocytes
- Workshop No. V NK14, S329
- Entrez Gene ID 960
- Storage Buffer Phosphate buffered saline with gelatin and 0.1% sodium azide.
- Regulatory Status RUO (GMP)
Regulatory Status Legend
Description
The CD44 antibody, clone L178, is derived from hybridization of Sp2/0 myeloma mouse cells with spleen cells from BALB/c mice immunized with TCR-γ/δ+ thymocytes.
The CD44 (Leu-44) antibody recognizes a cell-surface glycoprotein that exists in a variety of isoforms. It is synthesized as a molecule with a molecular weight of 37 kilodaltons (kDa). Upon glycosylation, it is converted to an 80- to 95-kDa form. Alternatively, a 180- to 200-kDa form results from the addition of chondroitin sulfate.
Format
FITC, fluorescein isothiocyanate, is a fluorochrome with a molecular weight of 389 Da. FITC is sensitive to pH changes and photobleaching. Due to nearly identical excitation and emission properties but different spillover characteristics, FITC and Alexa Fluor® 488 cannot be used simultaneously. FITC is relatively dim and should be reserved for highly expressed markers whenever possible.
Resources & Tools | ||||||
---|---|---|---|---|---|---|
Spectrum Viewer | Panel Designer | Spectrum Viewer | Download TDS | Regulatory Document Website |
Preparation and Storage
Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.
-
Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline — Third Edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.
-
Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR. 1988;37:377-388.